Philippines
+918265041513
+918265041513

Cifran 500mg (Ciprofloxacin) Quebec City — Broad-Spectrum Antibiotic Quebec Canada 2026

Cifran 500mg (Ciprofloxacin) – Quebec City, Quebec, Canada (2026)


Visit

Website: unnatipharmax.com
Phone: +91 82650 41513
Email: Unnatipharmax@gmail.com



PRODUCT NAME

Brand Name: Cifran 500mg
Generic Name: Ciprofloxacin 500 mg
Strength: 500 mg
Dosage Form: Tablets
Therapeutic Category: Fluoroquinolone Antibiotic



PRODUCT DETAILS

Cifran 500mg contains Ciprofloxacin 500 mg, a fluoroquinolone antibiotic used to treat susceptible bacterial infections. It works by inhibiting bacterial DNA replication, helping eliminate susceptible bacteria. Ciprofloxacin should be used only when prescribed by a qualified healthcare professional and is not effective against viral infections.

It may be prescribed for susceptible infections such as:

  • Urinary tract infections (UTIs)
  • Certain respiratory tract infections
  • Gastrointestinal bacterial infections
  • Skin and soft tissue infections
  • Bone and joint infections
  • Certain complicated bacterial infections when clinically appropriate

Because fluoroquinolones can carry important risks, their use should follow a healthcare professional's assessment of the benefits and risks.


PRODUCT SPECIFICATION

  
Brand NameCifran 500mg
Generic NameCiprofloxacin
Strength500 mg
Dosage FormTablet
RouteOral
Therapeutic ClassFluoroquinolone Antibiotic
PackagingBlister Pack
StorageStore below 25°C in a cool, dry place
PrescriptionRequired
Manufactured InIndia
Export AvailabilityWorldwide (where legally permitted)

KEY FEATURES

  • Contains Ciprofloxacin 500 mg
  • Fluoroquinolone antibiotic for susceptible bacterial infections
  • Oral tablet formulation
  • Manufactured in WHO-GMP compliant facilities
  • Quality-assured pharmaceutical product
  • Available for retail, wholesale, and bulk supply
  • Secure packaging for international export
  • Competitive export pricing
  • Worldwide shipping where legally permitted
  • Intended for use under medical supervision

INDUSTRY UPDATE  

The global antibiotic market continues to prioritize responsible antibiotic prescribing and efforts to reduce antimicrobial resistance (AMR). Fluoroquinolone antibiotics remain important treatment options for selected bacterial infections when other therapies are not appropriate or when supported by clinical guidelines.

Key developments in 2026 include:

  • Increased emphasis on antimicrobial stewardship programs
  • Greater use of culture and susceptibility testing to guide therapy
  • Continued monitoring of antimicrobial resistance trends worldwide
  • Growing demand for quality-assured generic antibiotics in regulated international markets
  • Ongoing investment in pharmaceutical manufacturing quality, regulatory compliance, and reliable global medicine supply chains 
Quebec City's CHU de Québec-Université Laval — the largest university hospital system in Eastern Canada outside Montreal — manages complex bacterial infections for the Quebec City region's 800,000 population. Quebec City's French Canadian heritage, its harsh winter that drives specific seasonal infection patterns, and its unique bilingual healthcare environment create distinctive antibiotic prescribing contexts. Cifran 500mg provides Quebec City residents with affordable Ciprofloxacin at dramatically reduced cost versus Quebec pharmacy pricing.
    Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
    ❓

     FAQ 1: What infections does Cifran 500mg treat in Quebec City's clinical setting and when does CHU de Québec prescribe it?

    Ciprofloxacin (Cifran 500mg) is a fluoroquinolone antibiotic with exceptionally broad gram-negative coverage — one of the most potent oral antibiotics available, with specific indications that CHU de Québec's antimicrobial stewardship programme carefully manages. Appropriate Cifran 500mg indications at CHU de Québec: complicated urinary tract infections (cystitis and pyelonephritis caused by E. coli, Klebsiella, or Proteus species where simpler antibiotics have failed or organism is resistant); infectious diarrhoea caused by Salmonella, Campylobacter, or Shigella (particularly traveller's diarrhoea in returning Quebec travellers — Quebec's significant winter sun travel to Mexico, Dominican Republic, and Cuba creates returning travellers with tropical infectious diarrhoea); prostatitis from gram-negative organisms (Cifran 500mg reaches high prostate concentrations due to its lipophilicity and active secretion into prostatic fluid); respiratory tract infections — reserved for quinolone-appropriate indications only (not first-line for community pneumonia in Quebec City; used for healthcare-associated pneumonia or when Mycoplasma/Chlamydophila are confirmed and macrolide-resistant); and anthrax post-exposure prophylaxis (relevant for CHU de Québec's bioterrorism preparedness protocols). CHU de Québec's stewardship restrictions on Cifran: CHU de Québec's antimicrobial pharmacists actively flag inappropriate Ciprofloxacin prescribing — its use for uncomplicated UTI when trimethoprim or nitrofurantoin would suffice, and for URTI where it is never appropriate. The quinolone-resistance concern: Ciprofloxacin resistance among E. coli in Quebec City's community UTI isolates has risen to 15-25% — a concerning trend that CHU de Québec's resistance surveillance programme actively monitors through collaboration with the Institut national de santé publique du Québec (INSPQ).
    Ciprofloxacin (Cifran 500mg) is a fluoroquinolone antibiotic with exceptionally broad gram-negative coverage — one of the most potent oral antibiotics available, with specific indications that CHU de Québec's antimicrobial stewardship programme carefully manages. Appropriate Cifran 500mg indications at CHU de Québec: complicated urinary tract infections (cystitis and pyelonephritis caused by E. coli, Klebsiella, or Proteus species where simpler antibiotics have failed or organism is resistant); infectious diarrhoea caused by Salmonella, Campylobacter, or Shigella (particularly traveller's diarrhoea in returning Quebec travellers — Quebec's significant winter sun travel to Mexico, Dominican Republic, and Cuba creates returning travellers with tropical infectious diarrhoea); prostatitis from gram-negative organisms (Cifran 500mg reaches high prostate concentrations due to its lipophilicity and active secretion into prostatic fluid); respiratory tract infections — reserved for quinolone-appropriate indications only (not first-line for community pneumonia in Quebec City; used for healthcare-associated pneumonia or when Mycoplasma/Chlamydophila are confirmed and macrolide-resistant); and anthrax post-exposure prophylaxis (relevant for CHU de Québec's bioterrorism preparedness protocols). CHU de Québec's stewardship restrictions on Cifran: CHU de Québec's antimicrobial pharmacists actively flag inappropriate Ciprofloxacin prescribing — its use for uncomplicated UTI when trimethoprim or nitrofurantoin would suffice, and for URTI where it is never appropriate. The quinolone-resistance concern: Ciprofloxacin resistance among E. coli in Quebec City's community UTI isolates has risen to 15-25% — a concerning trend that CHU de Québec's resistance surveillance programme actively monitors through collaboration with the Institut national de santé publique du Québec (INSPQ).
    ❓

     FAQ 2: How does Quebec City's winter travel culture — mass migration to warm destinations — create returning traveller infections requiring Cifran 500mg?

    Quebec City's brutal winters (averaging -12°C in January) drive one of Canada's highest per-capita rates of winter sun travel — Quebec families, retirees, and workers escape to Cuba, Dominican Republic, Mexico's Riviera Maya, and the Caribbean at rates that make "snowbird" travel a major Quebec City economic and cultural phenomenon. Returning traveller infections in Quebec City: traveller's diarrhoea (TD) is the most common travel-related illness — affecting 30-40% of Quebecers returning from Mexico, Dominican Republic, and Cuba's all-inclusive resorts; the causative organisms: Enterotoxigenic E. coli (ETEC) in 30-40% of TD cases; Campylobacter (increasingly common in Mexico and Caribbean resorts, with high rates of fluoroquinolone resistance now documented); Shigella and Salmonella (less frequent but more severe). Cifran 500mg for Quebec City's returning travellers: for ETEC-associated TD — Cifran 500mg twice daily for 3 days is highly effective, typically resolving diarrhoea within 24-48 hours; for Campylobacter TD from Mexico (where fluoroquinolone resistance is significant), Azithromycin is actually preferred over Cifran — CHU de Québec's travel medicine service advises returning Quebec travellers with severe diarrhoea to have stool cultures before antibiotic selection if clinically stable, to match antibiotic to organism. Pre-travel Cifran prophylaxis: CHU de Québec's Clinique de santé des voyageurs (Travel Health Clinic) does not routinely recommend Cifran prophylaxis for all Quebec travellers to Mexico — reserving it for high-risk travellers (immunocompromised, elderly) with access to treatment where physician contact would be difficult. Cifran 500mg from Unnati Pharmax serves Quebec City returning travellers who have CHU de Québec travel medicine physician prescription and need affordable standby antibiotic supply for subsequent travel episodes.
    ❓

     FAQ 3: What are the serious adverse effects of Cifran 500mg that Quebec City physicians and patients must be aware of?

    Ciprofloxacin carries a Health Canada Black Box Warning — the most serious safety communication — for tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects. These risks have significantly changed CHU de Québec's prescribing approach in recent years. Tendon damage (tendinitis and tendon rupture): Ciprofloxacin inhibits matrix metalloproteinases in tendons, reducing collagen cross-linking and causing tendon fragility — the Achilles tendon is most commonly affected; risk is highest in patients above 60, those on concurrent corticosteroids, transplant recipients, and patients with renal impairment. Quebec City's physically active population: Quebec City's outdoor culture — skiing in the Laurentians, cycling on the Plains of Abraham, cross-country skiing on the Valcartier Vacation Village trail — creates a physically active population where Achilles tendinopathy has severe functional consequences; CHU de Québec's pharmacists specifically warn Quebec City skiers and cyclists about Cifran's tendon risk and the instruction to stop immediately if tendon pain develops during Cifran use. Peripheral neuropathy: Cifran can cause persistent peripheral neuropathy (tingling, numbness, pain in extremities) that may not fully resolve after drug discontinuation — particularly in patients with pre-existing diabetic neuropathy or vitamin B12 deficiency. CNS effects: Cifran crosses the blood-brain barrier and can cause anxiety, insomnia, confusion, and rarely seizures — particularly relevant for Quebec City's elderly population and those on NSAIDs (which inhibit GABA at brain, synergising with Cifran's CNS effects). Health Canada's restricted indication update (2017 and ongoing): Health Canada has progressively restricted Cifran 500mg prescribing to situations where no safer alternative exists — CHU de Québec's pharmacists and prescribers follow these restricted indications strictly, limiting Cifran to situations where its efficacy advantage genuinely outweighs its risk profile.
    ❓

     FAQ 4: How does Cifran 500mg treat complicated UTI in Quebec City's Université Laval female student population?

    Université Laval's 47,000 students include a significant young female population — the peak demographic for urinary tract infections (UTI). The UTI burden at Laval: uncomplicated cystitis (simple bladder infection in young women without anatomical abnormality) is the most common bacterial infection presentation at Laval's student health service; first-line treatment is trimethoprim-sulfamethoxazole or nitrofurantoin — not Cifran 500mg; Cifran is reserved for complicated UTI at Laval's student health service. When Cifran 500mg is appropriate for Laval students: febrile UTI suggesting pyelonephritis (kidney infection — flank pain, fever above 38°C, rigors) — Cifran 500mg twice daily for 7 days is the RAMQ guideline first-line for outpatient pyelonephritis treatment; recurrent UTI in a Laval student with previous trimethoprim-resistant E. coli on urine culture — Cifran covers trimethoprim-resistant organisms; and UTI in a student with known urinary tract structural abnormality — complicated UTI requiring broader-spectrum coverage. RAMQ coverage for Cifran 500mg in Quebec City: RAMQ covers Ciprofloxacin for UTI indications for eligible Quebec residents — Laval students who are RAMQ-enrolled access Cifran at RAMQ co-payment rate. International Laval students: in the 3-month RAMQ waiting period, UTI is genuinely urgent — Laval Student Health Centre maintains a small antibiotic supply for emergency cases, but follow-up prescriptions through a Quebec City pharmacy require RAMQ or private payment; Cifran 500mg from Unnati Pharmax at dramatically reduced private cost serves international Laval students with pyelonephritis requiring outpatient Cifran who are not yet RAMQ-covered.
    ❓

     FAQ 5: What food, drug, and supplement interactions affect Cifran 500mg efficacy — important guidance for Quebec City patients?

    Ciprofloxacin has significant interactions with several common food components, medications, and supplements that substantially reduce its absorption — making CHU de Québec's patient education on these interactions clinically critical. Dairy and calcium chelation: Cifran forms insoluble chelates with divalent cations (calcium, magnesium, aluminium, iron, zinc) — dairy products (milk, yoghurt, cheese) taken within 2 hours of Cifran significantly reduce Cifran absorption by 30-50%; Quebec City's dairy-rich culture (the province's celebrated poutine, fromage en grains, and high milk consumption) creates a particularly relevant education need; patients must take Cifran either 1 hour before or 2 hours after dairy intake. Antacids and calcium supplements: antacid products containing aluminium, magnesium, or calcium hydroxide reduce Cifran absorption by up to 90% if taken together — patients using antacids must separate them from Cifran by a minimum of 6 hours. Coffee and caffeine: Cifran inhibits CYP1A2 — the primary caffeine-metabolising enzyme; concurrent Cifran and caffeine consumption significantly elevates plasma caffeine levels (by 3-4 fold), causing caffeine toxicity (palpitations, anxiety, insomnia, tremor); Quebec City's exceptionally high coffee consumption culture creates significant caffeine toxicity risk during Cifran courses — CHU de Québec's pharmacists specifically counsel Cifran patients to reduce coffee consumption to 1 cup maximum daily during the course. Theophylline interaction: Cifran's CYP1A2 inhibition also elevates theophylline levels in asthmatic patients using theophylline bronchodilator — relevant for Quebec City's elderly COPD population who may have theophylline prescriptions alongside Cifran courses. NSAIDs: concurrent NSAIDs (ibuprofen, naproxen — common OTC use in Quebec City) with Cifran increases CNS seizure risk through GABA receptor inhibition synergy; Quebec City patients are specifically counselled against ibuprofen use during Cifran 500mg courses.

    Website

    www.unnatipharmax.com

    www.medindiadropshipper.com

     

    Email Id

    unnatipharmax@gmail.com

     

    Contact Number

    +91-8265041513

    https://wa.me/918265041513

    Cifran-500-mg-Ciprofloxacin-Quebec-City
     2026-08-28T05:30:17

    Keywords